联系我们

论文查询结果	返回搜索

论文编号：	10760
作者编号：	2120162820
上传时间：	2018/12/10 10:39:53
中文题目：	KX生物医药公司融资策略的研究
英文题目：	Research on Financing Strategy of KX Biomedical Company
指导老师：	齐岳
中文关键字：	融资；生物医药行业；中小企业；策略
英文关键字：	Financing; Biomedical industry; Small and medium enterprises; measures
中文摘要：	生物医药行业是21世纪最活跃、影响最深远的新兴产业之一，也是国家战略性产业发展的核心方向，其对于提高我国的经济发展水平，转变经济增长模式，增强国民健康水平具有重要意义。 生物医药是技术密集型、资本密集型的产业，具有“三高一长”的特点，即高投入、高风险、长周期、高回报。其中，高投入和和长周期的两个特点使企业迫切需要大量资金作为支撑。我国生物医药行业发展起步较晚，行业中公司的规模大多为中小型，且国内的政策环境和金融环境均不够成熟，公司自身的管理水平需要提高，这些因素都使得公司在产品开发和市场营销推广过程中面临资金短缺的问题。探讨和研究我国生物医药企业，尤其是对中小型生物医药企业融资策略的研究，对于解决其普遍存在的融资问题具有参考价值，同时，对促进我国生物医药行业的健康发展，加快转变经济发展方式，具有重要的战略意义。 本文以国内外关于中小企业融资的理论和文献研究为基础，结合生物医药行业的发展现状、特点、行业资本需求分析以及国内外生物医药行业的融资渠道和现状，以KX生物医药公司为研究对象，通过分析公司的发展概况、融资现状及融资需求，并结合KX公司融资的内外部环境分析，进而得出其存在的融资问题，如融资渠道单一化，过分依赖风险投资；银行贷款等债务融资比例偏低；申请政府扶持资金有限。分析成因后，给出KX生物医药在今后开展融资的策略选择：提高内源融资比例，合理运用多种类型的债务融资方式，开展无形资产质押贷款，推进以香港上市为主要形式的股权融资，引入政府资助资金。而后从公司角度提出内部保障措施，如建立以信用体系为基础的银企关系；建立健全专业的融资管理体系；加强引智，促进项目开发。 KX生物医药公司的具体情况虽然是自身特有的，但所面临的问题可能是生物医药行业中小企业普遍存在的，通过分析和提出KX生物医药公司今后可以采取的融资策略和内部保障措施，本文也希望能够能够给生物医药行业的其他企660业解决融资问题，选择融资策略提供一定的参考。 关键词：融资；生物医药行业；中小企业；策略
英文摘要：	The bio-medical industry is one of the most active and far-reaching emerging industries in the 21st century. It is also the core direction of the country’s strategic industrial development. It is of great significance for improving China’s economic development level, transforming the economic growth model and enhancing the national health level. The bio-medical industry a technology-intensive, capital-intensive industry with the characteristics of “three highs and one long”, which refer to high investment, high risk, long cycle and high returns. Among them ,the two characteristics of high investment and long-term cycle make biomedical enterprises urgently need a large amount of funds as support. The development of biomedical industry in China started late. The scale of the company in the industry is mostly small and medium-sized, and the domestic policy environment and financial environment are not mature enough. The company's own management level needs to be improved. These factors make the company face the shortage of funds during the process of product development and marketing. To explore and study the biomedical enterprises in China, especially the research on the financing strategies of small and medium-sized biomedical enterprises, it has reference value for solving the common financing problems, and at the same time, there is an important strategic significance to promote the healthy development of the biomedical industry and accelerate the transformation of economic development mode. Based on the theory and literature research on SME financing at home and abroad, this paper combines the development status, characteristics, industry capital demand analysis of the bio-medical industry, as well as the financing channels and status quo of biomedical industry at home and abroad, taking KX Bio-Pharmaceutical Company as the research object. By analyzing the company's development profile, financing status and financing needs, and combining the internal and external environmental analysis of KX's financing, the financing problems existed, such as the simplification of financing channels, excessive dependence on venture capital, the low proportion of debt financing such as bank loans.; the application for government support is limited. After analyzing the causes, some financing strategies have are given for KX’s future financing such as increasing the proportion of endogenous financing, rationally using various types of debt financing methods, carring out intangible assets pledge loans, and promoting equity financing with Hong Kong listing as the main form. Introduce government-funded funds. Then, from the perspective of the company, internal safeguard measures are proposed, such as establishing a bank-enterprise relationship based on the credit system; establishing a sound professional financing management system; strengthening intelligence and promoting project development. Although the specific situation of KX biomedical company is unique to itself, the problems faced may be the widespread existence of SMEs in the biomedical industry. By analyzing and proposing the financing strategies and internal safeguard measures that KX Biopharmaceutical Company can adopt in the future, I hope that this paper can solve the financing problem for other companies in the biomedical industry and choose a financing strategy to provide some reference. Key Words: Financing; Biomedical industry; Small and medium enterprises; measures
查看全文：	预览  下载(下载需要进行登录)